Sandbox: Post-chemotherapy cognitive impairment
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Synonyms and keywords: Chemotherapy-induced cognitive dysfunction; Chemo brain; Chemo fog; Chemobrain
Overview
Post-chemotherapy cognitive impairment (also known as chemotherapy-induced cognitive dysfunction) is defined as the cognitive impairment that can result from chemotherapy treatment. Post-chemotherapy cognitive impairment is characterized by changes in memory, fluency, and other cognitive abilities that impeded their ability to function as they had pre-chemotherapy. Approximately 20-30% of patients that undergo chemotherapy experience some level of post-chemotherapy cognitive impairment. Recent studies suggest further investigation on the underlying mechanisms of cognitive impairment.
Historical Perspective
- Post-chemotherapy cognitive impairment was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
Classification
- There is no classification system for post-chemotherapy cognitive impairment.
Pathophysiology
- The pathogenesis of post-chemotherapy cognitive impairment is not fully understood.
- However, the underlying pathophysiology is believed to be caused by direct neurotoxicity.
- There are no genes associated with the development of post-chemotherapy cognitive impairment.
- On gross pathology, characteristic findings of post-chemotherapy cognitive impairment, include:
- No remarkable findings
- On microscopic histopathological analysis, characteristic findings of post-chemotherapy cognitive impairment, may include:
- Smaller tumor size
- Reduced cellularity
- Extensive cytoplasmic vacuolization causing tumor cells to resemble histiocytes
- Tumor necrosis
- Atrophy and marked nuclear atypia
Causes
- The causes for post-chemotherapy cognitive impairment remain unknown.[1]
Differentiating Post-Chemotherapy Cognitive Impairment from Other Diseases
- Post-chemotherapy cognitive impairment must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
- [Differential dx1]
- [Differential dx2]
- [Differential dx3]
Epidemiology and Demographics
- The prevalence of post-chemotherapy cognitive impairment is approximately [number or range] per 100,000 individuals worldwide.
- In [year], the incidence of post-chemotherapy cognitive impairment was estimated to be [number or range] cases per 100,000 individuals in [location].
Age
- Patients of all age groups may develop post-chemotherapy cognitive impairment.
- Post-chemotherapy cognitive impairment is more commonly observed among patients aged [age range] years old.
- Post-chemotherapy cognitive impairment is more commonly observed among [elderly patients/young patients/children].
Gender
- Post-chemotherapy cognitive impairment affects men and women equally.
- [Gender 1] are more commonly affected with post-chemotherapy cognitive impairment than [gender 2].
- The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
Race
- There is no racial predilection for post-chemotherapy cognitive impairment.
- Post-chemotherapy cognitive impairment usually affects individuals of the [race 1] race.
- [Race 2] individuals are less likely to develop post-chemotherapy cognitive impairment.
Risk Factors
- The most common risk factor in the development of post-chemotherapy cognitive impairment are number of cycles of chemotherapy.
Natural History, Complications and Prognosis
- The majority of patients with post-chemotherapy cognitive impairment remain asymptomatic for [duration/years].
- Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
- If left untreated, [#%] of patients with post-chemotherapy cognitive impairment may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
- Common complications of post-chemotherapy cognitive impairment include [complication 1], [complication 2], and [complication 3].
- Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with post-chemotherapy cognitive impairment is approximately [#%].
Diagnosis
Diagnostic Criteria
- The diagnosis of post-chemotherapy cognitive impairment is made when at least [number] of the following [number] diagnostic criteria are met:
- [criterion 1]
- [criterion 2]
- [criterion 3]
- [criterion 4]
Symptoms
- Post-chemotherapy cognitive impairment is usually asymptomatic.
- Symptoms of post-chemotherapy cognitive impairment may include the following:
- [symptom 1]
- [symptom 2]
- [symptom 3]
- [symptom 4]
- [symptom 5]
- [symptom 6]
Physical Examination
- Patients with post-chemotherapy cognitive impairment usually appear [general appearance].
- Physical examination may be remarkable for:
- [finding 1]
- [finding 2]
- [finding 3]
- [finding 4]
- [finding 5]
- [finding 6]
Laboratory Findings
- There are no specific laboratory findings associated with post-chemotherapy cognitive impairment.
- A [positive/negative] [test name] is diagnostic of post-chemotherapy cognitive impairment.
- An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of post-chemotherapy cognitive impairment.
- Other laboratory findings consistent with the diagnosis of post-chemotherapy cognitive impairment include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
Imaging Findings
- There are no [imaging study] findings associated with post-chemotherapy cognitive impairment.
- [Imaging study 1] is the imaging modality of choice for post-chemotherapy cognitive impairment.
- On [imaging study 1], post-chemotherapy cognitive impairment is characterized by [finding 1], [finding 2], and [finding 3].
- [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
Other Diagnostic Studies
- Post-chemotherapy cognitive impairment may also be diagnosed using [diagnostic study name].
- Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
Treatment
Medical Therapy
- There is no treatment for post-chemotherapy cognitive impairment; the mainstay of therapy is supportive care.
- The mainstay of therapy for post-chemotherapy cognitive impairment is [medical therapy 1] and [medical therapy 2].
- [Medical therapy 1] acts by [mechanism of action1].
- Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
Surgery
- Surgery is the mainstay of therapy for post-chemotherapy cognitive impairment.
- [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of post-chemotherapy cognitive impairment.
- [Surgical procedure] can only be performed for patients with [disease stage] post-chemotherapy cognitive impairment.
Prevention
- There are no primary preventive measures available for post-chemotherapy cognitive impairment.
- Effective measures for the primary prevention of post-chemotherapy cognitive impairment include [measure1], [measure2], and [measure3].
- Once diagnosed and successfully treated, patients with post-chemotherapy cognitive impairment are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].
References
- ↑ Aleah J. McHenry, MSN, RN. Management of Chemotherapy Induced Cognitive Impairment. http://www.oncolink.org/resources/article.cfm?id=1057 Accesed on May 18, 2016